NMS · Financial Statements

Spero Therapeutics, Inc. (SPRO) Financial Statements

$1.11 NMS: SPRO Market Cap $64.64M

Spero Therapeutics, Inc. most recently reported annual revenue of $60.0M, net profit of $9.0M. Revenue grew at an average annual rate of 46.1% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Spero Therapeutics, Inc.: net profit was positive in 2 of 10 reported years; operating margin moved from -9916.7% to -0.0%, a shift of +9916.7 percentage points; the most recent year shows net profit of $9.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$2.0M$4.0M$18.0M$9.0M$3.0M$49.0M$104.0M$48.0M$60.0M
Operating Expenses$34.0M$44.0M$47.0M$81.0M$88.0M$91.0M$91.0M$82.0M$121.0M$60.0M
Operating Profit$-33.0M$-42.0M$-43.0M$-63.0M$-79.0M$-88.0M$-42.0M$21.0M$-73.0M$0
Operating Margin-9916.7%-2108.6%-1079.3%-348.4%-847.9%-2865.5%-86.9%20.7%-152.9%-0.0%
Other Income$1.0M$2.0M$1.0M$2.0M$1.0M$-2.0M$-4.0M$4.0M$5.0M$9.0M
Interest$0$0$0$0$0$2.0M$3.0M$0$0$0
Depreciation$0$0$0$1.0M$1.0M$1.0M$1.0M$0$0$0
Profit Before Tax$-33.0M$-46.0M$-42.0M$-61.0M$-78.0M$-90.0M$-46.0M$25.0M$-69.0M$9.0M
Tax$0$790,000$0$0$0$0$0$10.2M$0$3.0M
Net Profit$-25.0M$-46.0M$-42.0M$-61.0M$-78.0M$-90.0M$-46.0M$23.0M$-69.0M$9.0M
EPS$-3.86$-17.82$-2.60$-3.31$-3.52$-2.91$-1.23$0.43$-1.27$0.15
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$25.0M$74.0M$4.0M$10.0M$13.0M$15.0M$6.0M$12.0M$3.0M$40.0M$0$0
Operating Expenses$27.0M$23.0M$18.0M$29.0M$32.0M$37.0M$21.0M$14.0M$11.0M$8.0M$8.0M$10.0M
Operating Profit$-2.0M$51.0M$-14.0M$-19.0M$-19.0M$-22.0M$-15.0M$-2.0M$-8.0M$31.0M$-8.0M$-10.0M
Operating Margin-7.6%68.7%-332.6%-186.9%-138.0%-144.4%-250.8%-20.7%-259.7%79.2%-2921.7%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-1.0M$52.0M$-13.0M$-18.0M$-17.0M$-21.0M$-14.0M$-2.0M$-7.0M$32.0M$-7.0M$-10.0M
Tax$-222.4M$750,000$0$0$1.7M$-1.4M$0$0$0$820,000$0$0
Net Profit$-3.0M$51.0M$-13.0M$-18.0M$-17.0M$-21.0M$-14.0M$-2.0M$-7.0M$32.0M$-7.0M$-10.0M
EPS$-0.06$0.96$-0.24$-0.33$-0.32$-0.39$-0.25$-0.03$-0.13$0.53$-0.13$-0.16

Over the 10 years reported for Spero Therapeutics, Inc., cash stood at $40.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 7.44 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$14.0M$93.0M$129.0M$106.0M$153.0M$171.0M$125.0M$182.0M$111.0M$69.0M
Current Assets$12.0M$87.0M$115.0M$95.0M$139.0M$158.0M$109.0M$131.0M$107.0M$67.0M
Cash$10.0M$87.0M$34.0M$30.0M$85.0M$113.0M$109.0M$76.0M$53.0M$40.0M
Inventory$0$-5.0M$-9.0M$0$0$0$-4.0M$0$0$0
Receivables$0$3.0M$1.0M$10.0M$0$3.0M$1.0M$51.0M$52.0M$25.0M
Fixed Assets$2.0M$1.0M$3.0M$7.0M$9.0M$8.0M$5.0M$4.0M$3.0M$1.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$82.0M$52.0M$42.0M$34.0M$0$47.0M$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$7.0M$9.0M$13.0M$32.0M$21.0M$83.0M$49.0M$75.0M$64.0M$10.0M
Current Liabilities$7.0M$8.0M$12.0M$27.0M$14.0M$19.0M$22.0M$37.0M$49.0M$9.0M
Borrowings$0$0$0$6.0M$8.0M$7.0M$7.0M$6.0M$4.0M$3.0M
Other Liabilities$7.0M$9.0M$13.0M$26.0M$14.0M$75.0M$42.0M$70.0M$60.0M$7.0M
Equity$8.0M$0$0$0$0$0$0$0$0$0
Reserves$10.0M$85.0M$116.0M$75.0M$132.0M$88.0M$76.0M$107.0M$46.0M$59.0M

For Spero Therapeutics, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $13.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-29.0M$-39.0M$-40.0M$-50.0M$-86.0M$-64.0M$-8.0M$-33.0M$-23.0M$-13.0M
Investing Cash Flow$-2.0M$-1.0M$-86.0M$29.0M$10.0M$8.0M$34.0M$0$0$0
Financing Cash Flow$9.0M$-5.0M$-1.0M$0$1.0M$47.0M$0$0$0$0
Net Cash Flow$5.0M$77.0M$-53.0M$-4.0M$55.0M$27.0M$-3.0M$-33.0M$-23.0M$-13.0M
Free Cash Flow$-30.0M$-39.0M$-42.0M$-50.0M$-86.0M$-64.0M$-8.0M$-33.0M$-23.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.06
EV / EBITDA2.62
FCF Yield28.42%
Quick Ratio6.12
Interest Coverage—
Return 1Y-33.53%
Return 3Y9.60%
Return 5Y-88.53%

Spero Therapeutics, Inc. (SPRO) financials — frequently asked questions

What is Spero Therapeutics, Inc.'s annual revenue?

Spero Therapeutics, Inc. (SPRO) reported annual revenue of $60.0M in its most recent fiscal year.

What is Spero Therapeutics, Inc.'s net profit?

Spero Therapeutics, Inc. (SPRO) reported net profit of $9.0M in its most recent fiscal year.

What is SPRO EV/EBITDA?

Spero Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 2.62.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
SPRO Overview SPRO Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.